First-in-Human Phase I Clinical Trial of SLC-391, a Novel and Selective AXL Inhibitor, in Patients with Advanced Solid Tumours

Zaihui Zhang, Donna Morrison, Lu Liang, Madhu Singh, Jun Yan, Natasha B. Leighl, Scott A. Laurie, Sébastien J. HottePharmaceuticals 2025 · DOI

TL;DR

This Phase I clinical trial investigated SLC-391, a novel AXL inhibitor, in patients with advanced solid tumors. The study found SLC-391 to be generally well-tolerated, with promising signs of clinical benefit, including stable disease in a significant portion of patients, supporting further investigation in combination therapies.

What Problem Does This Paper Address?

AXL is a receptor tyrosine kinase that plays a crucial role in cancer progression, including tumor growth, metastasis, immune evasion, and resistance to therapies. This makes AXL a highly sought-after target for new cancer treatments. While preclinical studies showed potent anti-tumor effects for SLC-391, a selective AXL inhibitor, its safety, tolerability, and preliminary efficacy in humans with advanced solid tumors had not yet been established. This study addresses the critical need to evaluate this novel drug in a clinical setting to determine its potential as a new therapeutic option.

Methods

This was a first-in-human, open-label, multi-center Phase I clinical trial (NCT03990454) employing a standard 3+3 dose escalation design. Patients received SLC-391 orally, either once daily (QD) at doses ranging from 25 mg to 175 mg, or twice daily (BID) at doses from 75 mg to 200 mg, in 21-day cycles. The primary objectives were to assess safety, tolerability, and determine the maximum tolerated dose (MTD). Secondary objectives included characterizing the pharmacokinetic (PK) profile and evaluating preliminary efficacy. Safety was monitored through adverse events (AEs), dose-limiting toxicities (DLTs), and laboratory evaluations. PK parameters were analyzed using non-compartmental methods. Efficacy was assessed using RECIST 1.1 criteria.

Datasets

Not discussed in the paper. The study involved human participants, and no specific datasets for training or evaluation were mentioned.

Key Insights and Ideas

  • AXL as a Promising Target: The study reinforces the importance of AXL as a therapeutic target in various cancers, given its role in multiple aspects of tumor progression and resistance.
  • SLC-391's Oral Bioavailability and Selectivity: The drug's oral administration and selective inhibition of AXL are key advantages, potentially leading to improved patient compliance and reduced off-target effects compared to less selective agents.
  • Generally Favorable Safety Profile: Despite being a novel agent, SLC-391 demonstrated a generally well-tolerated safety profile, with most adverse events being mild to moderate. This is crucial for a first-in-human study.
  • No MTD Reached: The fact that the MTD was not reached suggests a wide therapeutic window for SLC-391, allowing for exploration of higher doses or combination therapies in future studies.
  • Clinical Benefit Observed: The achievement of stable disease in a notable percentage of patients, some for extended periods, indicates that SLC-391 can exert a clinical effect even as monotherapy in heavily pre-treated patients.

Key Results

  • Patient Population: A total of 35 subjects with advanced solid tumors were enrolled. The most common primary tumor type was non-small cell lung cancer (NSCLC).
  • Safety and Tolerability:
    • 34 out of 35 subjects (97.1%) experienced at least one treatment-emergent adverse event (TEAE).
  • Three subjects (8.6%) experienced Grade 3 treatment-related adverse events (TRAEs).
  • Eight serious adverse events (SAEs) were reported in five subjects (14.3%).
  • Three dose-limiting toxicities (DLTs) were reported in two subjects: Grade 3 hematochezia (at 175 mg QD) and Grade 3 thrombocytopenia with Grade 1 hematuria (at 200 mg BID).
  • The 150 mg BID dose was well-tolerated with no DLTs or SAEs observed.
  • Pharmacokinetics (PK):
    • SLC-391 was rapidly absorbed with median Tmax values generally around 2.0 hours.
  • Plasma concentrations increased with dose and appeared to reach steady state by Day 21.
  • Dose proportionality was generally observed.
  • BID dosing showed less peak-to-trough variability compared to QD dosing.
  • Efficacy:
    • 12 out of 35 subjects (34.3%) achieved stable disease according to RECIST 1.1 or modified RECIST.
  • Durations of stable disease lasted up to 318 days on SLC-391 monotherapy.
  • The clinical benefit rate was 34.3%.

Limitations and Future Work

  • Limitations:
    • This was a Phase I study, primarily focused on safety and tolerability, with a relatively small sample size.
  • The MTD was not reached, which is a common outcome in early-phase trials but means the upper limit of safe dosing wasn't definitively established within this study's design.
  • The efficacy findings are preliminary, as this was not an efficacy-driven study.
  • Future Work:
    • The promising safety profile and observed clinical benefit provide a strong rationale for further investigation.
  • The study supports the planned Phase 1b/2a clinical investigation of SLC-391 in combination with pembrolizumab in patients with advanced or metastatic NSCLC (NCT05860296). This combination approach aims to leverage the potential of AXL inhibition to enhance anti-tumor immunity and overcome resistance to immunotherapy.

Summary updated

Abstract

<b>Background/Objectives:</b> AXL, a receptor tyrosine kinase of the TAM family, has emerged as a key target in cancer therapy due to its role in tumour growth, metastasis, immune evasion, and therapy resistance. SLC-391, a novel, orally bioavailable and selective AXL inhibitor, has demonstrated potent anti-tumour effects in preclinical studies. This first-in-human, open-label, multi-centre Phase I clinical trial (NCT03990454) was conducted to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of SLC-391 in patients with advanced solid tumours. <b>Methods:</b> Using a 3 + 3 design, SLC-391 was administered orally, either once daily (from 25 mg up to 175 mg QD) or twice daily (from 75 mg to 200 mg BID) in 21-day cycles. <b>Results:</b> Following single and repeated dosing, SLC-391 was generally well tolerated by subjects. The maximum tolerated dose (MTD) was not reached in this study. A total of 34/35 subjects experienced at least one TEAE. Three (8.6%) subjects experienced Grade 3 TRAEs that were considered related to SLC-391. Eight SAEs were reported in five (14.3%) subjects (seven Grade 3 SAEs and one Grade 2 SAE), in 150 mg QD (3/6, 50%), 175 mg QD (1/2, 50%), and 110 mg BID (1/3, 33.3%) cohorts. Four SAEs in three (8.6%) subjects led to dose interruption, drug withdrawal, or study discontinuation. Three DLTs were reported in two subjects: one subject experienced Grade 3 hematochezia (SUSAR/DLT) at 175 mg QD, and another subject experienced Grade 3 thrombocytopenia associated with Grade 1 hematuria at 200 mg BID. The median T<sub>max</sub> was 2.0 h. Plasma concentrations following multiple doses generally increased with higher doses and appeared to reach steady state by Day 21 and were generally dose-proportional. Twelve (12) out of 35 subjects with solid tumours achieved stable disease according to RECIST or mRECIST (mesothelioma), with durations of stable disease lasting up to 318 days on SLC-391 monotherapy. The clinical benefit rate was 34.3%. <b>Conclusions:</b> This first study of SLC-391 in adult subjects with advanced solid tumours demonstrated that a total daily dose of 300 mg (150 mg BID) of SLC-391 monotherapy was generally well tolerated, with no DLTs or SAEs observed at this dose. The drug's promising safety profile, along with stable disease reported for several subjects with advanced solid tumours, provides a strong rationale for the phase 1b/2a clinical investigation of SLC-391 in combination with pembrolizumab in subjects with advanced or metastatic non-small cell lung cancer (NSCLC) (NCT05860296).
BibTeX
@inproceedings{zhang2025first,
  author = {Zaihui Zhang and Donna Morrison and Lu Liang and Madhu Singh and Jun Yan and Natasha B. Leighl and Scott A. Laurie and Sébastien J. Hotte},
  title = {{First-in-Human Phase I Clinical Trial of SLC-391, a Novel and Selective AXL Inhibitor, in Patients with Advanced Solid Tumours}},
  booktitle = {Pharmaceuticals},
  year = {2025},
  doi = {10.3390/ph18121898},
}
Figure